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Abstract
Background and aims
Increased propionylcarnitine levels in newborn screening are indicative for a group of poten-
tially severe disorders including propionic acidemia (PA), methylmalonic acidemias and
combined remethylation disorders (MMACBL). This alteration is relatively non-specific,
resulting in the necessity of confirmation and differential diagnosis in subsequent tests.
Thus, we aimed to develop a multiplex approach for concurrent determination of 3-hydroxy-
propionic acid, methylmalonic acid and methylcitric acid from the same dried blood spot
(DBS) as in primary screening (second-tier test). We also set out to validate the method
using newborn and follow-up samples of patients with confirmed PA or MMACBL.
Methods
The assay was developed using liquid chromatography–tandem mass spectrometry and
clinically validated with retrospective analysis of DBS samples from PA or MMACBL
patients.
Results
Reliable determination of all three analytes in DBSs was achieved following simple and
fast (<20 min) sample preparation without laborious derivatization or any additional pipett-
ing steps. The method clearly distinguished the pathological and normal samples and
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differentiated between PA and MMACBL in all stored newborn specimens. Methylcitric acid
was elevated in all PA samples; 3-hydroxypropionic acid was also high in most cases.
Methylmalonic acid was increased in all MMACBL specimens; mostly together with methyl-
citric acid.
Conclusions
A liquid chromatography–tandem mass spectrometry assay allowing simultaneous determi-
nation of the biomarkers 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid
in DBSs has been developed. The assay can use the same specimen as in primary screen-
ing (second-tier test) which may reduce the need for repeated blood sampling. The pre-
sented preliminary findings suggest that this method can reliably differentiate patients with
PA and MMACBL in newborn screening. The validated assay is being evaluated prospec-
tively in a pilot project for extension of the German newborn screening panel (“Newborn
screening 2020”; Newborn Screening Center, University Hospital Heidelberg).
Introduction
Propionic acidemia (PA; OMIM 606054) and methylmalonic acidemias including methylma-
lonyl-CoA mutase, methylmalonyl-CoA epimerase and cobalamin (Cbl) A, B, C, D, F and J
deficiencies (MMACBL; OMIM 251000, 251120, 251100, 251110, 277400, 277410, 277380 and
614857, respectively) are rare but potentially severe autosomal recessive disorders of propio-
nate catabolism (Fig 1) [1–6]. Methylmalonyl-CoA mutase deficiency can be complete (MMA-
mut(0)) or partial (MMAmut(-)) [1]. The clinical symptoms of PA and MMACBL are widely
variable and, in many cases, potentially life-threatening [1, 5, 6]. Various organs including the
nervous and gastrointestinal systems, the heart and the kidney can be affected [1, 5, 6]. Accord-
ingly, an early diagnosis by means of newborn screening (NBS) has been recommended by the
American College of Medical Genetics and National Academy of Clinical Biochemistry [2–4]
for PA, MMAmut deficiency and Cbl A and B defects, disorders having the highest potential
for severe outcome [1, 5, 6].
In NBS, an increased propionylcarnitine (C3) level in dried blood spots (DBSs) is suggestive
for either PA or MMACBL [1]. However, C3 elevation is not specific for these disorders due to
an overlap of its concentration in affected and unaffected newborns, particularly in premature
infants, which results in high false-positive rates [1, 7]. The use of analyte ratios such as C3/
acetylcarnitine (C3/C2) improves specificity, but still cannot differentiate between PA and
MMACBL [1, 8]. This necessitates confirmation of primary screening results and differential
diagnosis using more specific assays [1].
Traditionally, confirmation of PA has been performed from urine by detecting elevated lev-
els of various biomarkers including 3-hydroxypropionic acid (3OHPA) and methylcitric acid
(MCA), together with normal methylmalonic acid (MMA) concentrations (Fig 1) [1]. In
MMACBL, urinary MMA and MCA are increased; 3OHPA may also be elevated (Fig 1) [1].
However, urine can only be obtained via patient recall which markedly delays time to diagno-
sis and initiation of treatment and may also generate unnecessary parental stress [1]. In turn,
methods using the same DBS specimen as in the primary screening (second-tier tests) may
reportedly reduce time to diagnosis and the number of recalls [9]. However, previous second-
tier assays for PA and MMACBL [10–17] did not allow concurrent measurement of these
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biomarkers from DBS and generally utilized time-consuming and laborious sample prepara-
tion [10–14].
Importantly, a simultaneous and selective measurement of all three relevant diagnostic bio-
markers from DBS could allow the evaluation of their individual diagnostic values in DBS for
differentiation between PA and MMACBL and as a result could reinforce the analytical confi-
dence of the diagnosis. In addition, the applied method must also be able to separate two
Fig 1. Biochemical pathway of propionate metabolism (simplified). 3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric
acid; Cbl: cobalamin. Drawn using Inkscape 0.91pre4 (Open Source Software licensed under the GNU General Public License).
https://doi.org/10.1371/journal.pone.0184897.g001
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additional interfering substances, lactic acid and succinic acid (isobaric with 3OHPA and
MMA, respectively), being highly abundant in blood [1].
Therefore, our aim was to develop a liquid chromatography–tandem mass spectrometry
(LC-MS/MS) assay for the simultaneous determination of the biomarkers 3OHPA, MMA and
MCA from DBS, while separating the isobaric metabolites lactic acid and succinic acid. We
also set out to keep sample preparation simple and fast for easier inclusion of the assay in the
routine workflow. To assess the relevance of the three biomarkers in DBS, we retrospectively
analyzed specimens from known patients with PA or MMACBL before and during therapy
using the successfully developed assay.
Materials and methods
Reagents
Unlabelled 3OHPA, lactic acid, succinic acid, MMA, MCA and zinc sulfate heptahydrate
(ZnSO4  7H2O) were purchased from Sigma-Aldrich (St. Louis, MO, USA); deuterated inter-
nal standards (ISs) d3-MMA from Cambridge Isotope Laboratories (Andover, MA, USA); d3-
lactic acid and d3-MCA from CDN Isotopes (Pointe-Claire, Quebec, Canada); methanol, ace-
tonitrile and formic acid (all ULC-MS grade) from Biosolve (Valkenswaard, The Netherlands).
Ultrapure water (18.2 MO.cm), filtered through a 0.22 μm pore size membrane, was obtained
from a Thermo Barnstead GenPure Pro UV-TOC/UF system (Thermo Fisher Scientific, Wal-
tham, MA, USA).
Sample preparation
Two spots 3.2 mm in diameter of each of the DBS calibrators, Quality Controls (QCs) and the
patient samples (corresponding to 6.4 μl blood) were punched out from filter cards and placed
into Merck Ultrafree-MC VV 0.1 µm centrifugal filter units (Darmstadt, Germany). The IS
working solution (composition: 20, 1.7, and 0.50 µM for d3-lactic acid, d3-MMA and d3-MCA,
respectively) was prepared fresh daily by a 5-fold dilution of a deuterated IS intermediate stock
solution (stored in aliquots at -20˚C) with methanol/water 50/50 (v/v). To each sample, 120 μl
IS working solution plus 10 μl 50 mM ZnSO4 solution (in methanol) were added. The samples
were sealed, vortexed for 5 min, and centrifuged for 10 min at 5000 × g in a Heraeus Biofuge
Pico centrifuge (Hanau, Germany) at ambient temperature. After removal of the lid and filter,
the tubes were placed directly into the autosampler. The analyte levels in DBS calibrators Cal0
to Cal6 (stored at -20˚C) were as follows: 0, 12.5, 25, 50, 100, 200, 400 μM for 3OHPA; 0, 1.25,
2.5, 5.0, 10, 20, 40 μM for MMA; and 0, 0.25, 0.50, 1.0, 2.0, 4.0, 8.0 μM for MCA, respectively.
The analyte levels in QC1, QC2 and QC3 (stored at -20˚C) were the following: 20, 60, 100 μM
for 3OHPA; 2.0, 30, 100 μM for MMA; and 0.40, 1.2, 4.0 μM for MCA, respectively. The prepa-
ration of standard stock solutions, DBS calibrators and QCs are further detailed in S1 Text.
LC-MS/MS instruments and settings
A Waters Acquity I-Class UPLC system (Binary Solvent Manager, thermostatic Column Man-
ager and FTN Sample Manager) and a Waters TQ-S triple quadrupole MS/MS were used, con-
trolled by MassLynx 4.1 software (all Waters, Milford, MA, USA). MS/MS data were evaluated
with TargetLynx 4.1 software (Waters, Milford, MA, USA).
The chromatographic separation of the analytes was performed on a Phenomenex Gemini
C6-Phenyl 150×2.0 mm, 3 μm analytical column and a SecurityGuard C6-Phenyl 20 mm I.D.
cartridge guard column (both Phenomenex, Torrance, CA, USA). Eluent A consisted of
ultrapure water plus 0.4% formic acid (ULC-MS grade). Eluent B consisted of methanol/
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acetonitrile 50/50 (both ULC-MS grade). Both eluents were prepared weekly. The column was
tempered to 25˚C. The autosampler settings were the following: injection volume: 5 μl; sample
compartment temperature: 5˚C. Gradient elution at a flow of 200 μl/min was performed by
changing %B as follows: 0.0-1.5 min: 10%; 1.5-2.5 min: 10% to 30%; 2.5-4.0 min: 30%; 4.0-4.1
min: 30% to 10%; 4.1-10.0 min: 10%. Experience with further extraction solvents, columns and
eluents, derivatization and isocratic elution obtained during method development are pro-
vided in S1 Table.
MS/MS settings were optimized by means of consecutive syringe infusions of 10 μM solu-
tions for each analyte and IS, dissolved in ultrapure water. All analytes and ISs were measured
in negative electrospray ion mode; the dwell times were 20 ms each. Optimized MS/MS set-
tings are summarized in Table 1. The final ion source settings were the following: desolvation
gas flow = 800 L/h; cone gas flow = 150 L/h; nebulizer = 6.0 bar; capillary voltage = 2.5 kV; des-
olvation temperature = 650˚C; source temperature = 150˚C.
Application of the LC-MS/MS test on patient samples with PA and
MMACBL and external quality control samples
Clinical validation of the LC-MS/MS assay was performed retrospectively using 79 DBS sam-
ples from 32 different patients with PA or MMACBL from the NBS and Metabolic Centers in
Heidelberg (Germany), Szeged (Hungary) and Zurich (Switzerland). In 14 patients, the new-
born specimens prior to therapy initiation were also available (PA: n = 4; CblB n = 1; CblC
n = 9); all other samples were obtained during therapy. Storage duration of the patient speci-
mens before second-tier analysis in median (range) was 0.61 (0.01-8.90) years. For additional
characterization of samples, we used the first–tier acylcarnitine profiles (electrospray ioniza-
tion-MS/MS [18–20]) determined both at time of blood sampling at the respective site pro-
viding the specimen, as well as after storage (measured at the NBS Centers Heidelberg and
Szeged). First–tier cutoff values for C3 and C3/C2 in the respective laboratories were the fol-
lowing: Heidelberg 5.5 μM and 0.22; Szeged: 5.75 μM and 0.26; and Zurich: 6.0 μM and 0.17.
The 3OHPA, MMA and MCA levels were also measured in External Quality Assurance DBS
samples for NBS (n = 7) from ERNDIM.
The validated assay is currently being evaluated prospectively in a pilot project for the
extension of the German NBS panel named “Newborn screening 2020” at the NBS Center Hei-
delberg. In that prospective study, the reported LC-MS/MS assay is being applied as second-
tier test using the same DBS specimen as in the primary screening.
All procedures followed were in accordance with the ethical standards of the Helsinki Dec-
laration of 1975, as revised in 2000. Written informed consent for regular newborn screening
Table 1. Optimized MS/MS settings in the second-tier LC-MS/MS assay (negative electrospray ion mode).
Analyte Parent mass (Da) Daughter mass (Da) Cone voltage (V) Collision voltage (V)
3OHPA 88.9 59.0 -48 -10
Lactic acid 88.9 43.0 -46 -11
d3-Lactic acid 92.0 45.1 -46 -11
Succinic acid 116.9 72.9 -47 -12
MMA 117.0 73.0 -30 -12
d3-MMA 120.0 76.1 -30 -10
MCA 205.0 125.1 -35 -13
d3-MCA 208.0 87.1 -35 -18
3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric acid.
https://doi.org/10.1371/journal.pone.0184897.t001
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had been obtained from the parents of all individuals at time of blood sampling if required by
national legislation. The anonymized, retrospective re-analysis of the specimens in the present
study was approved by the Ethical Committees of the University of Szeged (217/2016-SZTE)
and the University Children’s Hospital Zurich (2014-0211). At the University Hospital Heidel-
berg, parents of patients under treatment gave written informed consent for sample analysis
for establishment of the second-tier strategies for the study NBS 2020. The study NBS 2020
was approved by the Ethical Committee of the University of Heidelberg (S-533/2015).
Results
Method validation
The linearity, the limit of detection (LOD) and the lower limit of quantitation (LLOQ) were
tested with various concentrations of calibrator DBSs (n = 10). LOD was defined as S/N = 3;
LLOQ was defined as the lowest concentration measured with a coefficient of variation (CV)
lower than 20%. The coefficient of determination for linearity (R2) was 0.9702 for 3OHPA,
0.9946 for MMA and 0.9926 for MCA (Table 2). The LOD and LLOQ values for 3OHPA,
MMA and MCA were: 15 μM, 1.5 μM, 0.05 μM; and 20 μM, 2.5 μM, 0.07 μM, respectively
(Table 2).
The retention times of 3OHPA and MMA were 2.4 min and 3.9 min, respectively. Of note,
MCA and d3-MCA are both detected in two chromatographic peaks (Figs 2–4). In case of d3-
MCA, the first peak at 3.7 min reportedly corresponds to the (2R, 3S) and (2S, 3R) stereoiso-
mers; and the second peak at 4.2 min to (2R, 3R) and (2S, 3S) [21, 22]. Of the four possible ste-
reoisomers of unlabeled MCA, only two, (2R, 3S) and (2S, 3S) are physiological [21, 22]. The
respective MCA and d3-MCA peaks were summed during the evaluation of the
concentrations.
The resolution of critical isobaric analyte pairs was determined using the Cal5 DBS calibra-
tor (n = 10), by averaging retention times (t1 and t2) and peak widths at half peak height (w0.5,1
and w0.5,2) in 10 injections. Resolution (Rs) was calculated via the following equation: Rs = 1.18
(t2-t1)/(w0.5,1+w0.5,2). The critical isobaric pair succinic acid and MMA were baseline resolved
(Rs = 2.7). As the isobaric metabolites 3OHPA and lactic acid had specific daughter ions and
therefore specific MRM transitions (Table 1), a chromatographic separation was not necessary
for their determination. Despite extensive efforts, however, the 3OHPA peak could not be fully
chromatographically separated from an interference peak having identical MRM transitions
(Rs<1.0) (peaks 0 and 1 on Figs 2–4).
Interday and intraday precisions, variations between multiple injections of the same sample
extract and recoveries were examined in QCs at three different concentrations (n = 10)
(Table 3). With the exception of the lowest MMA level (2.0 μM), the CV values were lower
than 15% (Table 3). The recoveries ranged from 99.0-109.4%, except for the lowest 3OHPA
level (20 μM) (Table 3).
Table 2. Assay validation in calibrator dried blood spots (n = 10).
Analyte Linearity (R2) LOD (μM) LLOQ (μM) Retention time (min)
3OHPA 0.9702 15 20 2.4±0.01
MMA 0.9946 1.5 2.5 3.9±0.01
MCA 0.9926 0.05 0.07 3.7±0.01 and 4.2±0.01
3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric acid; R2: coefficient of determination; LOD: limit of detection; LLOQ: lower
limit of quantitation.
https://doi.org/10.1371/journal.pone.0184897.t002
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Testing of the present assay with clinical specimens
For the determination of normal biomarker concentrations in the second-tier test, we used
residual DBS samples (n = 250) after primary NBS for amino acids and acylcarnitines. Blood
samples (collected between 36-72 hours of age) with C3 levels lower than or equal to 4.5 μM
and ratios C3/C2 lower than or equal to 0.18 were randomly selected and anonymized prior to
the analysis. The 99.9th percentiles in DBS of these newborns, chosen as cutoff values for the
second-tier test, were: 3OHPA: 38.13 μM; MMA: 2.29 μM; and MCA: 0.08 μM.
Results of the clinical validation of the LC-MS/MS assay by means of retrospective analysis
of stored patient samples are summarized in Table 4. The second-tier test clearly distinguished
the pathological and normal samples and differentiated between PA and MMACBL in all new-
born specimens, despite marked degradation of C3 after storage (up to 95%) [23, 24], as com-
pared with C3 levels at time of blood sampling. Similarly, most specimens obtained during
Fig 2. LC-MS/MS chromatogram of DBS from a healthy newborn. Peak 1: 3-hydroxypropionic acid (3OHPA); peak 2: lactic acid; peak 3: succinic acid;
peak 4: methylmalonic acid (MMA); peaks 5a and 5b: methylcitric acid (MCA); peak 0: interfering peak; DBS: dried blood spot. Numbered black peaks:
unlabelled analytes; numbered unfilled peaks: deuterated internal standards. All intensities (Y-axes) have been normalized to 4*105 cps for better
comparability (not on the inserted zoom-in figures) and have been plotted against retention time (X-axes). Chromatograms were generated by MassLynx 4.1
(Waters, Milford, MA, USA) and modified using Inkscape 0.91pre4 (Open Source Software licensed under the GNU General Public License).
https://doi.org/10.1371/journal.pone.0184897.g002
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therapy showed biomarker patterns characteristic for the respective disorder. As concerns PA
samples, 3OHPA was normal in 2 out of 4 untreated newborn PA specimens and in 7 out of 21
PA samples on therapy. In these cases, only the elevated MCA could confirm the underlying
disease. It has to be considered, that all four newborn PA specimens were subject to long-term
storage (range 3.45-8.90 years). Storage time before analysis in the two NBS PA samples with
normal 3OHPA was especially long (8.86 and 8.90 years).
Of note, in four MMACBL cases under treatment (MMAmut(-) n = 1; CblC n = 3), the sec-
ond-tier results were still indicative of the disorder when the initial first-tier C3 and C3/C2 val-
ues were already in the normal range. In five additional patients under therapy (CblB n = 3;
CblC n = 2), the first-tier and second-tier results were both normal. Representative LC-MS/
MS chromatograms of DBS specimens from a healthy newborn, a PA and a MMAmut(0)
patient are presented in Figs 2–4, respectively.
Fig 3. LC-MS/MS chromatogram of DBS from a PA patient. Peak 1: 3-hydroxypropionic acid (3OHPA); peak 2: lactic acid; peak 3: succinic acid; peak 4:
methylmalonic acid (MMA); peaks 5a and 5b: methylcitric acid (MCA); peak 0: interfering peak; DBS: dried blood spot; PA: propionic acidemia. Numbered
black peaks: unlabelled analytes; numbered unfilled peaks: deuterated internal standards. All intensities (Y-axes) have been normalized to 4*105 cps for
better comparability (not on the inserted zoom-in figures) and have been plotted against retention time (X-axes). Chromatograms were generated by
MassLynx 4.1 (Waters, Milford, MA, USA) and modified using Inkscape 0.91pre4 (Open Source Software licensed under the GNU General Public License).
https://doi.org/10.1371/journal.pone.0184897.g003
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Testing of the present assay with external quality control samples
The 3OHPA, MMA and MCA levels were measured in External Quality Assurance DBS sam-
ples for NBS (n = 7) from ERNDIM. The second-tier test clearly differentiated between PA
and MMACBL in all External Quality Assurance specimens (Table 5).
Discussion
Despite potential benefits of NBS for PA and MMACBL [1, 25], these disorders are currently
screened for in only few European countries (Austria, Belgium, Denmark, Hungary, Iceland,
Portugal and Spain) [4, 26]. This is in part attributable to relatively high false-positive rates if
NBS for these disorders is based solely on C3 results [1]. The relative non-specificity is due to
an overlap of C3 concentrations in normal and affected individuals, particularly in prematures
[1, 7]. Even if the specificity can be improved if the levels of other biomarkers such as free car-
nitine, C2, palmitoylcarnitine or methionine are also taken into account in respective ratios
Fig 4. LC-MS/MS chromatogram of DBS from a MMAmut(0) patient. Peak 1: 3-hydroxypropionic acid (3OHPA); peak 2: lactic acid; peak 3: succinic
acid; peak 4: methylmalonic acid (MMA); peaks 5a and 5b: methylcitric acid (MCA); peak 0: interfering peak; DBS: dried blood spot; MMAmut(0):
methylmalonyl-CoA mutase deficiency (complete). Numbered black peaks: unlabelled analytes; numbered unfilled peaks: deuterated internal standards. All
intensities (Y-axes) have been normalized to 4*105 cps for better comparability (not on the inserted zoom-in figures) and have been plotted against retention
time (X-axes). Chromatograms were generated by MassLynx 4.1 (Waters, Milford, MA, USA) and modified using Inkscape 0.91pre4 (Open Source Software
licensed under the GNU General Public License).
https://doi.org/10.1371/journal.pone.0184897.g004
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with C3 [1, 8], some cases may still be missed reportedly [27]. Thus, there is a need for assays
that allow confirmation and differential diagnosis of primary screening results for PA and
MMACBL [1]. Urine organic acid analysis by means of gas chromatography–mass spectrome-
try has been most commonly used, which can simultaneously detect various diagnostic bio-
markers including 3OHPA, MMA and MCA (Fig 1) [1]. Other assays have used serum or
plasma for the determination of one or two, but not all three, of these relevant biomarkers [28,
29].
In NBS, however, the DBS is the standard sample type due to its advantages, including the
ease of sample collection, transportation, storage and stability [30]. The analysis of the same
DBS specimen as in the primary screening (second-tier testing) may also reportedly decrease
the necessity for recalls, shorten time to diagnosis and improve the cost- and time-effectiveness
of screening [9, 31]. Moreover, previous studies highlighted the importance of avoiding unnec-
essary recalls by reporting significant increases in family anxiety and frequency of hospitaliza-
tion in subjects with false-positive NBS results [32, 33].
Table 3. Assay validation in dried blood spots using quality control samples at three concentrations (n = 10).
Analyte Analyte level (μM) CV (%) interday CV (%) intraday CV (%) between injections Recovery (%)
3OHPA 20 9.2 10.8 10.7 136.8
60 14.3 13.4 8.0 99.2
100 6.2 10.6 7.9 106.8
MMA 2.0 32.9 20.2 10.6 108.1
30 9.3 9.1 5.0 99.0
100 12.9 10.5 3.3 105.0
MCA 0.40 10.2 9.1 2.2 102.3
1.2 6.9 6.5 2.7 104.4
4.0 11.3 6.0 2.0 109.4
3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric acid; CV: coefficient of variation.
https://doi.org/10.1371/journal.pone.0184897.t003
Table 4. Results of dried blood spot samples from patients with known diagnosis: Retrospective analysis of NBS specimens (untreated) and sam-
ples during therapy. Data are provided as medians (ranges).
First-tier test (initial analysis shortly
after blood sampling)
Second-tier test
Biomarker C3 (μM) C3/C2 3OHPA (μM) MMA (μM) MCA (μM)
Cutoff 5.8 (5.5-6.0) 0.22 (0.17-0.26) 38.13 2.29 0.08
NBS Controls (n = 250) 1.9 (0.7-4.3) 0.08 (0.04-0.18) n.d. (n.d.-38.8) 0.50 (n.d.-2.3) 0.02 (n.d.-0.08)
NBS PA (n = 4) 14.7 (10.4-25.0) 0.51 (0.24-1.94) 153.2 (20.9-367.2) 1.8 (n.d.-2.0) 2.06 (0.11-2.85)
NBS CblB (n = 1) 6.3 0.31 42.1 21.9 0.04
NBS CblC (n = 9) 7.1 (2.9-10.1) 0.39 (0.24-2.26) 33.2 (n.d.-117.3) 28.9 (5.1-640.3) 0.29 (0.04-1.40)
Treated PA (n = 21) 24.9 (3.2-80.7) 1.12 (0.23-4.31) 78.7 (n.d.-775.2) 0.1 (n.d.-1.6) 1.72 (0.11-7.00)
Treated MMAmut(0) (n = 4) 39.2 (5.0-48.4) 1.04 (0.45-1.24) 86.6 (31.6-136.3) 1727.6 (846.3-3464.4) 3.65 (0.75-8.85)
Treated MMAmut(-) (n = 11) 7.3 (3.4-12.0) 0.43 (0.20-0.57) n.d. (n.d.-41.8) 22.8 (4.6-49.6) 0.08 (0.02-0.15)
Treated CblA (n = 2) 5.9 (5.2-6.6) 0.41 (0.30-0.52) 27.9 (21.9-33.9) 70.0 (10.8-129.2) 0.28 (0.16-0.39)
Treated CblB (n = 17) 15.6 (1.3-23.3) 0.88 (0.08-1.44) 40.4 (n.d.-68.8) 193.2 (n.d.-460.8) 0.32 (n.d.-0.55)
Treated CblC (n = 10) 4.3 (1.1-8.8) 0.37 (0.08-1.62) 24.7 (n.d.-43.1) 9.5 (n.d.-78.0) 0.11 (n.d.-0.47)
NBS: newborn screening; PA: propionic acidemia; Cbl: cobalamin; MMAmut: methylmalonyl-CoA mutase deficiency; C3: propionylcarnitine; C2:
acetylcarnitine; 3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric acid; n.d.: not detectable.
https://doi.org/10.1371/journal.pone.0184897.t004
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To the best of our knowledge, the LC-MS/MS assay presented here is the first to have multi-
plexed three relevant biomarkers pathognomonic for PA and MMACBL in DBS (3OHPA,
MMA and MCA) in one run, taking into account the separation of the physiological interfer-
ing metabolites. Most previous assays using DBS detected MMA and/or MCA, but not in com-
bination with 3OHPA [10–14, 16]. Determination by LC-MS/MS of 3OHPA was reported by
two earlier studies which, in contrast with the present method, did not include MCA [15, 17].
To improve quantitation further, we have used a total of three ISs (one for each biomarker)
instead of a single IS in these earlier reports [15, 17]. This change may reportedly improve reli-
ability of the assay especially for high analyte levels where, if only one IS is used, suppression of
a single IS would affect quantitation of all other analytes [34].
As concerns sample preparation, previous methods generally utilized time-consuming and
laborious derivatization steps [10, 11, 13, 14] or liquid-liquid extraction [12]. In our assay,
these steps have been eliminated to achieve a very simple and fast (<20 min) sample prepara-
tion protocol to minimize errors and increase robustness without any special equipment or
further pipetting steps.
Even if our instrument would have been able to perform two-dimensional (2D) chromatog-
raphy with ultra-high performance, the assay was deliberately developed using one-dimen-
sional (1D) configuration with conventional HPLC settings. This approach, together with
simple sample preparation, is expected to improve inter-lab transferability and robustness for
an easier inclusion of this assay in the daily routine.
Importantly, due to multiplexing of the biomarkers, our assay allows the evaluation of the
individual diagnostic value of 3OHPA, MMA and MCA in the same DBS in the diagnosis and
follow-up of PA and MMACBL. As for PA in the present study, MCA was increased all new-
born PA samples (n = 4) as well as in External Quality Assurance specimens with PA (n = 3)
and all specimens obtained during therapy (n = 21). 3OHPA was also increased in many PA
cases. However, in 2 out of 4 untreated newborn PA samples and in 7 out of 21 PA specimens
under therapy, only the elevation of MCA, but not 3OHPA, could be detected, in contrast with
an earlier study [15]. Of note, PA specimens with elevated MCA but normal 3OHPA origi-
nated from PA patients having milder phenotypes. This was also indicated by their lower C3/
C2 ratios at time of blood sampling (newborn: range 0.24-0.50, treated: 0.23-0.55) as compared
with PA samples having both MCA and 3OHPA increased (newborn: range 0.52-1.94, treated:
0.96-4.31). However, all four newborn PA specimens were subject to long-term storage (range
3.45-8.90 years), leading up to a 95% decrease in the C3 levels, in line with previous reports
Table 5. Results of External Quality Assurance dried blood spot samples (n = 7).
Second-tier test Diagnosis according to second-tier test result
Biomarker 3OHPA (μM) MMA (μM) MCA (μM)
Cutoff 38.13 2.29 0.08
ERNDIM No. 1 90.33 n.d. 3.36 PA
ERNDIM No. 2 35.62 4277.03 4.30 MMACBL
ERNDIM No. 3 91.41 n.d. 2.44 PA
ERNDIM No. 4 32.66 24.57 0.21 MMACBL
ERNDIM No. 5 117.15 3892.14 8.50 MMACBL
ERNDIM No. 6 64.79 0.98 1.32 PA
ERNDIM No. 7 39.68 24.55 0.22 MMACBL
3OHPA: 3-hydroxypropionic acid; MMA: methylmalonic acid; MCA: methylcitric acid; n.d.: not detectable; PA: propionic acidemia; MMACBL: methylmalonic
acidemia or combined remethylation disorder.
https://doi.org/10.1371/journal.pone.0184897.t005
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[23, 24]. It may therefore be hypothesized that pre-analytical issues could have markedly con-
tributed to the lack of detection of 3OHPA in the two NBS samples. It has not been elucidated
in the literature whether alterations of C3 are paralleled with those of 3OHPA, MMA and
MCA in DBS stored in the long-term. MMA was reported to be stable for at least 1 year in
DBS [12], and MCA for at least 3 weeks [11]. In case of PA patients under treatment, our
observations might also be attributable to relative metabolic stability under treatment and con-
comitant therapy with carnitine increasing the renal elimination of the relevant metabolites
[1]. Thus, stored newborn and treated PA samples in our study could only be correctly identi-
fied if the decision was based on an elevation of MCA. However, these observations may be
irrelevant in the analysis of freshly obtained samples. Therefore, in our ongoing prospective
study (“Newborn screening 2020”), we set out to assay emerging fresh specimens from further
PA patients with mild or more severe phenotypes to clarify the roles of these factors, as well as
the diagnostic value of the biomarkers.
On the other hand, all retrospectively examined newborn (n = 10) and External Quality
Assurance specimens (n = 4) with MMACBL could be clearly distinguished from normal sam-
ples based on elevated MMA concentrations; this was accompanied by increased MCA levels
in most cases (n = 11 out of 14). MMA levels were only moderately elevated and MCA was
normal in one untreated newborn with CblB and two with CblC. MMA was also elevated in
most MMACBL samples obtained during therapy (n = 39 out of 44, including four with nor-
mal first-tier results); in 32 out of 39 specimens together with increased MCA levels. In five
additional patients under treatment (CblB n = 3; CblC n = 2), the first-tier and second-tier
results were both normal. Thus, in our sample set containing both mild and more severe phe-
notypes, MMA appears to be superior as diagnostic parameter for the detection of MMACBL
in DBS samples from NBS, with MCA being complementary and supporting the decision in
most but not all cases.
As concerns maternal vitamin B12 deficiency, such patients are expected to be partially
identified by the suggested second-tier strategy, as at least severe cases show elevation of C3
and MMA on NBS [35, 36]. Moreover, a clear benefit of early detection and treatment for both
the child and the mother in severe maternal vitamin B12 deficiency has been reported [37–39].
Thus, in our opinion, the identification of these patients may be regarded as a further advan-
tage of the proposed strategy, in spite of a reported increase in false-positive rates [35–39].
Accordingly, in our prospective study “Newborn screening 2020” maternal vitamin B12 defi-
ciency is explicitly included as one of the target disorders; the impact on false-positive rates is
also under evaluation.
Taken together, our preliminary findings from this retrospective analysis suggest that this
assay could reliably identify patients with PA and MMACBL in the present set of NBS samples.
Also, most specimens obtained during therapy showed biomarker patterns characteristic for
the respective disorder. However, 3OHPA was normal in a relevant number of newborn PA
samples–presumably influenced by pre-analytical changes during long-term storage–and also
in PA patients under therapy, while MCA could still confirm the presence of PA. As these ret-
rospective results may not be directly applicable for the analysis of freshly obtained samples,
the validated assay is being applied prospectively as a second-tier test in our pilot project
“Newborn screening 2020” at the University Hospital Heidelberg. In addition, that prospective
study is expected to provide data on effects of the presented second-tier strategy in NBS on
false-positive rates, frequency of recalls and time to diagnosis. More experience in such larger
studies representing a wider range of disorders and prospective evaluation of the described
method are needed to clarify the relevance of each biomarker in DBS, the reliability of the pre-
sented assay to identify patients in the NBS setting and the potential effect on false-positive
rates in premature and term newborns.
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Conclusions
In conclusion, an LC-MS/MS assay has been developed for the concurrent determination of
the relevant biomarkers pathognomonic for PA and MMACBL in DBS (3OHPA, MMA and
MCA), while separating the interfering metabolites lactic acid and succinic acid. Sample prep-
aration is simple and fast (<20 min); no special equipment, derivatization or complicated
pipetting steps are required. The assay can use the same DBS specimen as in the primary
screening and can therefore be integrated in NBS as a second-tier test to reduce the number of
recalls. The method was validated using clinical samples from known patients (newborn speci-
mens before therapy and samples under treatment) and External Quality Assurance speci-
mens. The presented preliminary findings suggest that application of this assay can reliably
identify and differentiate patients with PA and MMACBL in NBS samples. The validated assay
is currently being evaluated prospectively as second-tier test in a pilot project for the extension
of the German NBS panel (“Newborn screening 2020”) at the NBS Center of the University
Hospital Heidelberg.
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